Viraday
Emtricitabine · Tenofovir Disoproxil · Efavirenz
Efavirenz, emtricitabine and tenofovir tablets for HIV-1 infection. Combining three antiretrovirals lowers the chance of resistance.
- Category
- HIV Management
- Active ingredients
- Emtricitabine · Tenofovir Disoproxil · Efavirenz
- Route
- Oral use
- Form
- Tablet
- Strengths
- 1.1gm
Prescription and consultation requirements for Viraday vary by destination and are determined by the fulfilment partner.
Viraday details
- Alternative names
- emtricitabine, tenofovir, efavirenz
- Therapeutic class
- Nucleoside Analog and Non-Nucleoside Reverse Transcriptase Inhibitor Combination
- Pharmacological class
- Antiretroviral Combination
- Minor side effects
- dizziness; headache; insomnia
- Moderate side effects
- vivid dreams; rash; diarrhoea
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Cipla Ltd
- Onset Time
- 2–4 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Rifampin; Simvastatin; St. John's Wort
- Age restrictions
- Approved for adults weighing over forty kilograms.
Contraindications
severe renal impairment; concurrent highly CYP3A4-dependent therapies; hepatic failure
Serious side effects
lactic acidosis, requires immediate medical attention; severe hepatotoxicity, requires immediate medical attention; suicidal ideation, requires immediate medical attention
Patient summary
Efavirenz, emtricitabine and tenofovir tablets for HIV-1 infection. Combining three antiretrovirals lowers the chance of resistance.
Mechanism of action
Combines emtricitabine and tenofovir to terminate the viral DNA chain with efavirenz to inhibit reverse transcriptase non-competitively.
Pregnancy and breastfeeding
Pregnancy: Avoid in first trimester. Discontinue breastfeeding to prevent transmission. Breastfeeding: Confirm breastfeeding suitability with a qualified clinician or pharmacist before use.